The Full Wiki

More info on Dalbavancin

Dalbavancin: Wikis

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 171500-79-1
ATC code J01XA04
PubChem 16134410
Chemical data
Formula C 88H100Cl2N10O28  
Mol. mass 1755.634 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes Intravenous

Dalbavancin (INN, trade name Zeven) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[1]

It possesses in vitro activity against a variety of Gram-positive pathogens[2][3] including MRSA and MRSE.[4] It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[5]

On September 9, 2008, Pfizer announced that it will withdraw all marketing applications in order to conduct another Phase 3 clinical trial.[6]

References and notes

  1. ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
  2. ^ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMID 17362476.  
  3. ^ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci 21 (1): 78–88. PMID 18166524.  
  4. ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
  5. ^ UPDATE 1-Pfizer says US FDA wants more data on antibiotic
  6. ^ Pfizer Inc. (2008-09-09). "Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial". Press release. Retrieved 2008-09-11.  

Got something to say? Make a comment.
Your name
Your email address